Catalyst Event
Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/28/2026, 12:00:00 AM
Announced that its Class 1 innovative drug, Luzhunolei Sodium Tablets (SHR4640), was approved for marketing by the National Medical Products Administration of China. This is the first domestically developed high-selectivity URAT1 inhibitor for treating hyperuricemia in gout patients. This approval is expected to have a >=5% price impact due to the drug's market potential. expected
Korean Translation
자체 개발 1급 혁신 신약 '루즈노레나트륨정(SHR4640)'이 중국 국가약품감독관리국(NMPA)으로부터 시판 허가를 받았다고 발표함. 이는 통풍 환자의 고요산혈증 치료를 위한 중국 최초의 자체 개발 고선택성 URAT1 억제제임. 시장 잠재력에 따라 5% 이상의 주가 영향이 예상됨. 예상됨
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM